Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Harpoon Therapeutics Inc (HARP)

Harpoon Therapeutics Inc (HARP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 389,605
  • Shares Outstanding, K 16,932
  • Annual Sales, $ 31,920 K
  • Annual Income, $ -67,730 K
  • 60-Month Beta 2.11
  • Price/Sales 2.28
  • Price/Cash Flow N/A
  • Price/Book 20.82
Trade HARP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -8.76
  • Most Recent Earnings $-0.46 on 11/09/23
  • Latest Earnings Date 03/25/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.52
  • Number of Estimates 5
  • High Estimate -0.03
  • Low Estimate -0.74
  • Prior Year -5.50
  • Growth Rate Est. (year over year) +90.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.32 +3.09%
on 02/09/24
23.21 -0.86%
on 03/07/24
+0.67 (+3.00%)
since 02/08/24
3-Month
8.44 +172.63%
on 12/12/23
23.21 -0.86%
on 03/07/24
+14.07 (+157.38%)
since 12/08/23
52-Week
3.11 +639.87%
on 10/12/23
23.21 -0.86%
on 03/07/24
+15.76 (+217.38%)
since 03/08/23

Most Recent Stories

More News
Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

Investors are still excited about obesity treatments and weight-management drugs.

MRK : 131.95 (+0.15%)
LLY : 777.96 (-0.03%)
NVO : 128.40 (+0.27%)
HARP : 23.01 (+0.09%)
This 1 Bullish Move by Merck Could Drive Growth for Years to Come

It's buying a company with sophisticated biotechnology platforms that could drive lots of growth -- eventually.

AMGN : 284.32 (-0.69%)
MRK : 131.95 (+0.15%)
HARP : 23.01 (+0.09%)
Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise, Monday, 1/8/2024

Stocks that traded heavily or had substantial price changes on Monday: Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise

HARP : 23.01 (+0.09%)
ANSS : 347.16 (-0.22%)
MKKGY : 35.2300 (+1.44%)
ALK : 42.99 (+2.33%)
BA : 192.99 (+0.54%)
Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data and Big Tech Earnings

December S&P 500 futures (ESZ23) are down -0.76%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.92% this morning as the benchmark U.S. 10-year yield hit 5% for the first time since 2007 while...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
SEDG : 70.98 (+1.85%)
AXP : 227.69 (-0.03%)
RF : 21.04 (+1.74%)
KNX : 55.02 (+2.65%)
MSFT : 420.72 (-0.17%)
GOOGL : 150.93 (+0.04%)
V : 279.08 (+0.02%)
KO : 61.18 (+0.25%)
META : 485.58 (-1.68%)
BA : 192.99 (+0.54%)
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -7.28% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

JAZZ : 120.42 (-0.07%)
HARP : 23.01 (+0.09%)
Chinook Therapeutics (KDNY) Reports Q1 Loss, Tops Revenue Estimates

Chinook (KDNY) delivered earnings and revenue surprises of -6.25% and 292.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

KDNY : 40.39 (+0.22%)
HARP : 23.01 (+0.09%)
Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ARDX : 7.30 (-1.48%)
HARP : 23.01 (+0.09%)
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of 10.87% and 246.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ACRS : 1.2400 (-1.59%)
HARP : 23.01 (+0.09%)
New Strong Buy Stocks for January 27th

GWRS, EVBG, SPLK, RELL and HARP have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2023.

RELL : 9.21 (+0.33%)
SPLK : 156.90 (+0.25%)
GWRS : 12.84 (-0.31%)
EVBG : 34.83 (+0.06%)
HARP : 23.01 (+0.09%)
Why Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) could be a great choice. It is one of the several stocks...

HARP : 23.01 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body's immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform,...

See More

Key Turning Points

3rd Resistance Point 23.05
2nd Resistance Point 23.04
1st Resistance Point 23.02
Last Price 23.01
1st Support Level 22.99
2nd Support Level 22.98
3rd Support Level 22.96

See More

52-Week High 23.21
Last Price 23.01
Fibonacci 61.8% 15.53
Fibonacci 50% 13.16
Fibonacci 38.2% 10.79
52-Week Low 3.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar